Polatuzumab vedotin (Pola) is a novel antibody-drug conjugates (ADC) consisting of a CD79b-directed antibody linked to monomethyl auristatin E. Pola in combination with R-CHP (Pola-R-CHP) has been approved as a first-line treatment for previously untreated and R/R DLBCL patients. Here, POLA1 is linked to diffuse large B-cell lymphoma.